News stories about Catalyst Pharmaceuticals (NASDAQ:CPRX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.6636493157951 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Catalyst Pharmaceuticals (CPRX) opened at 2.67 on Friday. The company’s market capitalization is $225.76 million. The firm has a 50-day moving average of $2.59 and a 200 day moving average of $2.42. Catalyst Pharmaceuticals has a one year low of $0.94 and a one year high of $3.20.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. Equities research analysts predict that Catalyst Pharmaceuticals will post ($0.23) earnings per share for the current fiscal year.
Several research analysts have commented on CPRX shares. SunTrust Banks, Inc. restated a “buy” rating and issued a $5.00 price objective on shares of Catalyst Pharmaceuticals in a report on Tuesday, September 5th. Roth Capital set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. Piper Jaffray Companies set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $5.50.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Catalyst Pharmaceuticals (CPRX) Share Price” was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/2957281/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-catalyst-pharmaceuticals-cprx-share-price.html.
In other news, insider Patrick J. Mcenany acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was purchased at an average cost of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the acquisition, the insider now directly owns 4,471,026 shares of the company’s stock, valued at approximately $11,535,247.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.79% of the company’s stock.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.